Phase I, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2017
Price : $35 *
At a glance
- Drugs OTS 167 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors OncoTherapy Science
- 10 Apr 2017 Status changed from active, no longer recruiting to completed.
- 05 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.